Dr. Weber has been professionally connected with the life sciences for over 35 years, starting at the Technical University in Berlin, Germany, then at the Max Planck Institute in Berlin, Germany, at California Institute of Technology (Caltech) in Pasadena, and the University of California (Berkeley and San Francisco). Since 1985, he has applied his knowledge to the business world as a consultant to the pharmaceutical and biotech industries.

In 1985, Dr. Weber co-founded BioQuest LLC, a San Francisco-based retained executive search firm, which he continues to support in its ongoing growth. BioQuest assists emerging and established medical device, biotechnology, pharmaceutical and healthcare service companies to identify, evaluate and hire executive talent—the business leaders who grow successful companies in today's changing healthcare market. Over the years, Dr. Weber has worked with well-known venture capital, pharma and biotech companies, helping them build executive teams across all functional areas. As Managing Partner & Practice Group Leader of the Company’s Biopharmaceutical Practice Group, he helped establish BioQuest’s reputation for quality of service, technical expertise and broad knowledge of the industry, all features that continue to characterize the Company’s services.

From 2000 to early 2003, Dr. Weber worked with TechnoVenture Management, a bi-continental Venture Capital firm with offices in Munich, Germany, and Boston, Massachusetts, advising them on investments from their Life Sciences Fund V.

Since 2002, Dr. Weber has expanded his activities into connecting entrepreneurial executives with new products/promising technologies, and risk capital to create new companies. He first helped establish Acumen Pharmaceuticals, Inc., a firm developing novel and promising treatment to reverse the ravaging damage of dementia and Alzheimer's disease. He also serves on its Board of Directors, advising management on a number of strategic issues. Although based on a very new scientific paradigm at the time, Acumen’s concepts subsequently gained wider recognition in scientific and industry circles, which in 2003 led to a $150M collaboration with Merck on the development of therapeutic antibodies and vaccines to prevent Alzheimer’s disease.

In 2003, Dr. Weber also began to advise the Biomedical Development Corporation (BDC), a company with the charter of commercializing discoveries from the University of California and other scientific institutions in the SF Bay Area. BDC is designed to select promising laboratory discoveries in the healthcare area and to nourish them to the state of commercial proof of concept, thereby bridging the gap between early scientific discovery and the development of new medical devices, life science technologies, and new therapeutic drugs. BDC plans to provide financial and managerial resources needed to accomplish this task and is currently seeking several million dollars in funding.

Most recently, Dr. Weber helped build Certus Pharmaceuticals, a company that develops medicines to treat liver, ovarian, and peritoneal cancer with drugs that show excellent safety and efficacy profiles without the debilitating side effects of the currently used chemotherapeutic treatments. In 2004, Dr. Weber joined Certus’ scientific founder and recruited the Company’s Board of Directors, the beginning of an SAB, and helped formulate the company’s business and funding strategy. Currently, Dr. Weber serves as a Board member, helping to raise Certus’ Series A funding.

Prior to his industrial career, Dr. Weber created and directed a collaborative research effort between UC Berkeley and the San Francisco Medical Center (UCSF) aimed at an understanding of the conversion of sunlight into chemical energy. Together with his group, he co-discovered, described and isolated a new bacteriorhodopsin-like pigment that transports ions in the presence of sunlight against large salt gradients, thereby generating and storing electrochemical energy.

In 1973, the German government awarded Dr. Weber a generous fellowship that enabled him to join Nobel Laureate Max Delbrück at the California Institute of Technology in Pasadena, California. Together they investigated the molecular mechanisms of sensory transduction pathways in fungal model organisms.

Jürgen earned his Doctorate in Biochemistry at the Max Planck Institute for Molecular Genetics in Berlin-Dahlem and at the Freie Universität Berlin, Germany. He also holds an MS degree in Chemistry and Chemical Engineering from the Technical University of Berlin and an MBA degree in General Management from John F. Kennedy University.